A*STAR PATENTS

The subject disclosure is directed to techniques for enhancing the selectivity and efficacy of therapeutic polymers against a broad spectrum of pathogens and cancer cell lines. According to an embodiment, a method is provided that comprises forming a therapeutic polymer based on polymerization of a plurality of therapeutic monomers, wherein the therapeutic polymer provides a therapeutic functionality. The method further comprises attaching biotin to the therapeutic polymer, resulting in a biotin-functionalized therapeutic polymer, wherein the biotin-functionalized therapeutic polymer provides greater therapeutic efficacy relative to the therapeutic polymer.

A fluid jet dispenser using at least two multilayer piezoelectric actuators is provided. The fluid jet dispenser includes a dispensing head and an electrical driver. The dispensing head includes at least two d31-mode multilayer piezoelectric actuators, a displacement magnifying element mechanically coupled to the d31-mode multilayer piezoelectric actuators, a piston, and a nozzle. More preferably, the two d31-mode multilayer piezoelectric actuators operate in an anti-phase condition. The electrical driver is electrically coupled to the d31-mode multilayer piezoelectric actuators for displacing the actuators in directions substantially perpendicular to polarization of piezoelectric layers in the d31-mode multilayer piezoelectric actuators in response to charging and discharging of the actuators by the electrical driver, to generate a fast movement of the piston to jet a pressurized fluid out of the nozzle of the dispensing head.

The present invention relates to humanised antibodies that bind PRL3.

The present invention provides methods for the prediction of in vivo cell-specific toxicity of a compound that combines high-throughput imaging of cultured cells, quantitative phenotypic profiling, and machine learning methods. More particularly, the invention provides a method for the prediction of in vivo renal proximal tubular-, bronchial-epithelial-, and alveolar-cell-specific toxicities of a soluble or particulate compound that comprises contacting cultured human kidney and pulmonary cells with the compound at a range of concentrations, then labeling the cells with DNA, ?H2AX and actin markers and obtaining textural features, spatial correlation features, ratios of the markers, intensity features, cell count and morphology, estimating dose response curves and performing automatic classification of the compound using a random-forest algorithm.

There is provided a holographic security element including a substrate; and an array of nano-reflectors configured to form a pattern on the substrate and to generate a holographic image corresponding to the pattern at a predetermined distance from the substrate when irradiated with a predetermined light source. In particular, the array of nano-reflectors is configured to generate the holographic image at the predetermined distance to have a size that is larger than a size of the pattern. There is also provided a method of forming the holographic security element, and an article having one or more holographic security elements incorporated therein.

Anti-TIM-3 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.

"The present invention generally relates to a method for analyzing and identification of the plurality of lipids in a sample that is profiled using a combined Liquid Chromatography-Mass Spectrometry (LC-MS) technique

The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof. In particular, the present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to ERBB2. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.

There is provided a microfluidic device comprising: a plurality of wells, each well comprising one opening to function as an inlet and an outlet for the well, wherein each opening is in fluid communication with a common fluidic channel, and wherein each opening is connected to the common fluidic channel via an isolation channel, and wherein the plurality of wells is arranged on the device in a radially symmetrical pattern. There is also provided a system and method comprising the device.

The present invention relates to antisense oligonucleotides for modulating the activity of PRDM15 and use thereof in the treatment of cancer. In particular, said antisense oligonucleotides are capable of inducing the skipping of an exon of a PRDM15 mRNA. The present invention also relates to a method for determining prognosis in a patient with cancer, or selecting a therapeutic strategy for a patient with cancer, by assessing the level of PRDM15 nucleic acid, protein or activity in a sample.